Dinaciclib (SCH727965)

Catalog No.S2768 Synonyms: PS-095760

Dinaciclib (SCH727965) Chemical Structure

Molecular Weight(MW): 396.49

Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.

Size Price Stock Quantity  
In DMSO USD 272 In stock
USD 170 In stock
USD 470 In stock
USD 670 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 22 Publications

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.
Targets
CDK2 [1]
(Cell-free assay)		 CDK5 [1]
(Cell-free assay)		 CDK1 [1]
(Cell-free assay)		 CDK9 [1]
(Cell-free assay)
1 nM 1 nM 3 nM 4 nM
In vitro

Dinaciclib is also a potent DNA replication inhibitor that blocks thymidine (dThd) DNA incorporation in A2780 cells with IC50 of 4 nM. Dinaciclib strongly suppresses phosphorylation of Rb on Ser 807/811 at concentrations >6.25 nM, which is in agreement with the observation that 4 nM concentrations are required for 50% inhibition of dThd DNA incorporation in the same cell model. Significantly, complete suppression of Rb phosphorylation is correlated with the onset of apoptosis, as indicated by the appearance of the p85 PARP cleavage product in cells exposed to >6.25 nM Dinaciclib. Dinaciclib is active against a broad spectrum of human tumor cell lines. [1] Addition of Dinaciclib during hydroxyurea exposure also suppresses accumulation of γ-H2AX, in a dose-dependent manner. [2] Dinaciclib inhibits melanoma cell proliferation, and drives melanoma cells into massive apoptosis. [3] Dinaciclib induces the apoptosis of several osteosarcoma cell lines including those resistant to doxorubicin and dasatinib. Dinaciclib attenuates the phosphorylation of RNAP II at serine 2 and the phosphorylation of the CDK inhibitor p27Kip1 at threonine 187. Reductions in phosphorylation activity occurrs at 12 - 40 nM Dinaciclib (4 to 16 hours post-Dinaciclib addition). Dinaciclib also reduces the phosphorylation of Rb at serine 807/811. Dinaciclib induces the apoptosis of mock- and p53-depleted U2OS cells to a similar extent. [4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CA46 MV;BdI9xfG:|aYOgRZN{[Xl? MmfMNVAxKG6P NWi3ZZJFOjRiaB?= NVHMc28xcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> MWCyOVI5QTh6Nx?=
Kasumi-1 NG\wcGZCeG:ydH;zbZMhSXO|YYm= MojINVAxKG6P NYewb3oxOjRiaB?= NFrQSXBqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 M37WZVI2Ojh7OEi3
U937 M3jOb2Z2dmO2aX;uJGF{e2G7 NWPvfItNOi93L{GwJI5O NGTXdZY{KGh? MnXuZoxw[2u|IHnu[JVkfGmxbjDv[kBZSlBvMYOgZY5lKGSxd37zeJJm[W1idHHy[4V1ew>? NFPKZZYzPDN4MkS2OS=>
8226 NFTwU3RHfW6ldHnvckBCe3OjeR?= MkjtNk82NzFyIH7N NGOzOnc1KGh? NIXV[mFjdG:la4OgbY5lfWO2aX;uJI9nKFiEUD2xd{BidmRiZH;3cpN1emWjbTD0ZZJo\XS| NYqyVmRoOjR|NkK0OlU>
H929 NIWzPFlHfW6ldHnvckBCe3OjeR?= MkP1Nk82NzFyIH7N MnXMOEBp MknlZoxw[2u|IHnu[JVkfGmxbjDv[kBZSlBvMYOgZY5lKGSxd37zeJJm[W1idHHy[4V1ew>? MkfxNlQ{PjJ2NkW=
K562 NF;xR2FHfW6ldHnvckBCe3OjeR?= MnHDNU42NzNxODDuUS=> NIH2flY3KGh? MnWzZoxw[2u|IHnu[JVkfGmxbjDv[kBZSlBvMYOgZY5lKGSxd37zeJJm[W1idHHy[4V1ew>? M33kT|I1OzZ{NE[1
BaF3/Bcr-abl NF7jXnlHfW6ldHnvckBCe3OjeR?= M{LB[VEvPS9|L{igcm0> NFLpTnc3KGh? NXrl[XZ{[myxY3vzJIlv\HWldHnvckBw\iC[QmCtNZMh[W6mIHTve45{fHKnYX2geIFz\2W2cx?= M33hNlI1OzZ{NE[1
U937  M{nvOmZ2dmO2aX;uJGF{e2G7 NEn0TpczNzFyIH7N MWKzJIg> M3\mZ4Jtd2OtczDpcoR2[3Srb36gc4YhYEKSLUHzJIFv\CCmb4fud5Rz\WGvIIThdodmfHN? MWeyOFM3OjR4NR?=
1205Lu M{X4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnBVmIyOC9|MDDuUS=> NE\SXnA4OiCq NV\yXXlWcW6qaXLpeJMh[2WubDDndo94fGhiYX7kJJN2en[rdnHs NFqxe3IzOzV{N{KyOS=>
WM1366 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVqxNE8{OCCwTR?= NHHNSpQ4OiCq MliwbY5pcWKrdIOgZ4VtdCCpcn;3eIgh[W6mIIP1dpZqfmGu NF73UZAzOzV{N{KyOS=>
RD MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLiUpJKSzVyPUiuNkBvVQ>? MWKyNlMyPTJ2MB?=
Rh41 MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFyLkWgcm0> NInUcGQzOjNzNUK0NC=>
Rh18 NUfndW5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTFyLkWgcm0> MnvlNlI{OTV{NEC=
Rh30 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXLTWM2OD17IH7N NX;aeoo1OjJ|MUWyOFA>
BT-12 NUHkR|FFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRThwNTDuUS=> NVr2NZI5OjJ|MUWyOFA>
CHLA-266 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTdwMzDuUS=> MVSyNlMyPTJ2MB?=
TC-71 NYTJdplqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXXTWM2OD1|Lkmgcm0> M4TBcFIzOzF3MkSw
CHLA-9 Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fLdmlEPTB;ODDuUS=> NWHjcWdUOjJ|MUWyOFA>
CHLA-10 M3[xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;1T3hGUUN3ME22MlMhdk1? MXmyNlMyPTJ2MB?=
CHLA-258 NE\QcZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDaNnZKSzVyPUmuPUBvVQ>? Mo\GNlI{OTV{NEC=
GBM2 M1TW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfZUYhKSzVyPU[uOUBvVQ>? NFj6OWEzOjNzNUK0NC=>
NB-1643 NHHHd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTNwMzDuUS=> MViyNlMyPTJ2MB?=
NB-EBc1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rhPWlEPTB;NzDuUS=> NUD5WFVJOjJ|MUWyOFA>
CHLA-90 NHzM[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH4OY8zUUN3ME23MlUhdk1? MVWyNlMyPTJ2MB?=
CHLA-136 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTlwODDuUS=> MVyyNlMyPTJ2MB?=
NALM-6 M1jjXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHW2[nRKSzVyPUSuOkBvVQ>? NH;hXXIzOjNzNUK0NC=>
COG-LL-317 NGXRPYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTqTWM2OD14LkWgcm0> M3fwfVIzOzF3MkSw
RS4;11 M4WzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTVwMTDuUS=> NFzEU5UzOjNzNUK0NC=>
MOLT-4 M3zjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHOy[ZdKSzVyPUmuN{BvVQ>? MkDNNlI{OTV{NEC=
CCRF-CEM NYTVeldnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7qSXJKSzVyPUWuOkBvVQ>? NETZSo0zOjNzNUK0NC=>
Kasumi-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTRwNTDuUS=> M174PFIzOzF3MkSw
Karpas-299 MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPKW3BCUUN3ME2zMlkhdk1? NIXoR|YzOjNzNUK0NC=>
Ramos-RA1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfv[HBKSzVyPUeuPUBvVQ>? M3zsbFIzOzF3MkSw
MIAPaCa-2 M4LUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljxO|IhcA>? MW\HTVUxRTFyIH7N NHP2cZIzOTd4OEe3PS=>
Pa20C  M3;mZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWS2ZXkyPzJiaB?= MUXHTVUxRTJyIH7N NF33PZEzOTd4OEe3PS=>
ML-1 NGLGR3RCeG:ydH;zbZMhSXO|YYm= MWixMVExODBibl2= MUC0JIg> Mkn0bY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= MUiyNVc3QDd5Nx?=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
Mcl-1 / Bcl-2 / Bcl-xl / Bax / Bak / PUMA / Noxa; 

PubMed: 28714472     


H196 cells treated with doxorubicin for the indicated times were assessed by immunoblot analysis. 

Cleaved PARP / c-Myc; 

PubMed: 25289887     


Immunoblot analysis of A2780 cells during the 5 hr time-course treatment of Dinaciclib (100 nM).

Survivin; 

PubMed: 28207834     


Western blot analysis was performed in cells treated with dinaciclib (25 nM) or vehicle for the indicated time. The levels of Mcl-1, Bcl-xL and survivin were evaluated in BHP7-13, WRO82-1 and 8505C cells.

RNAP II (P-Ser2/P-Ser5); 

PubMed: 25289887     


Immunoblot analysis of A2780 cells during the 5 hr time-course treatment of Dinaciclib (100 nM).

28714472 25289887 28207834
Growth inhibition assay
Cell viability; 

PubMed: 27378523     


(a) Six typical NB cell lines were treated with increasing concentrations of dinaciclib for 48 hrs. Cell viability was then measured by the Cell Counting Kit-8 (CCK-8) assay. P-values < 0.01 (**) or P < 0.001 (***) (Student's t-test, two-tailed) were indicated. (b) The IC50 values of dinaciclib on each cell line listed were calculated based on the data in (a).

Cell viability; 

PubMed: 28361959     


(a-c) The number of cells after dinaciclib treatment. Cell number in 49 fields (7 × 7) was calculated and shown in the graph (n = 4). (a) Total cell number. **p < 0.01 vs control. (b) Number of OCT4 positive cells. **p < 0.01 vs control. (c) Number of OCT4 negative cells. n.s., not significant. (d) The percentage of OCT4 positive cells. **p < 0.01 vs control. *p < 0.05 vs 6 nM.

27378523 28361959
Immunofluorescence
cyclin B1 / α-tubulin / Aurora A; 

PubMed: 28207834     


(B) Cells were treated with dinaciclib (25 nM) or placebo for 24 h and stained with fluorescent antibodies against DAPI (blue), cyclin B1 (red) and α-tubulin (green). Cyclin B1 level was significantly reduced after treatment of dinaciclib in prophase cells of BHP7-13, WRO82-1 and 8505C. (C) Cells were treated with dinaciclib (25 nM) or placebo for 24 h and stained with fluorescent antibodies against DAPI (blue), Aurora A (red) and α-tubulin (green). Aurora A level was significantly reduced after treatment of dinaciclib in BHP7-13, WRO82-1 and 8505C cells in prophase. Scale bar, 10 μm.

OCT4; 

PubMed: 28361959     


Representative images of OCT4 positive cells (red). Nuclei were stained with Hoechst (blue). Scale bars = 200 μm.

28207834 28361959
In vivo Dinaciclib i.p. administration at 8, 16, 32, and 48 mg/kg daily for 10 days results in tumor inhibition by 70%, 70%, 89%, and 96%, respectively. Dinaciclib MED (minimum effective dose) appears to be <8 mg/kg. Dinaciclib is well tolerated, and the maximum body weight loss in the highest dosage group is 5%. Dinaciclib has dose-dependent antitumor activity in vivo, and that nearly complete inhibition of tumor growth occurs at a dose level below the MTD (maximum tolerated dose). Dinaciclib has a short plasma half-life in mouse. [1]

Protocol

Kinase Assay:[1]
+ Expand

Cyclin/CDK kinase assay:

Recombinant cyclin/CDK holoenzymes are purified from Sf9 cells engineered to produce baculoviruses that express a specific cyclin or CDK. Cyclin/CDK complexes are typically diluted to a final concentration of 50 μg/mL in a kinase reaction buffer containing 50 mM Tris-HCl (pH 8.0), 10 mM MgCl2, 1 mM DTT, and 0.1 mM sodium orthovanadate. For each kinase reaction, 1 μg of enzyme and 20 μL of a 2-μM substrate solution (a biotinylated peptide derived from histone H1) are mixed and combined with 10 μL of diluted Dinaciclib. The reaction is started by the addition of 50 μL of 2 μM ATP and 0.1 μCi of 33P-ATP. Kinase reactions are incubated for 1 hour at room temperature and are stopped by the addition of 0.1% Triton X-100, 1 mM ATP, 5 mM EDTA, and 5 mg/mL streptavidin-coated SPA beads. SPA beads are captured using a 96-well GF/B filter plate and a Filtermate universal harvester. Beads are washed twice with 2 M NaCl and twice with 2 M NaCl containing 1% phosphoric acid. The signal is then assayed using a TopCount 96-well liquid scintillation counter.
Cell Research:[1]
+ Expand
  • Cell lines: A2780 cells
  • Concentrations: 0 μM -5 μM
  • Incubation Time: 24 hours
  • Method: A2780 cells are maintained in DMEM plus 10% fetal bovine serum and passaged twice weekly by detaching the monolayer with trypsin-EDTA. One hundred microliters of A2780 cells (5 × 103 cells) are added per well to a 96-well Cytostar-T plate and incubated for 16 hours to 24 hours at 37 °C. Dinaciclib is serially diluted in complete media plus 2% 14C-labeled dThd. Media are removed from the Cytostar T plate; 200 μL of various Dinaciclib dilutions are added in quadruplicate; and the cells are incubated for 24 hours at 37 °C. Accumulated incorporation of radiolabel is assayed using scintillation proximity and measured on a TopCounTM.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Nude mice bearing A2780 tumors
  • Formulation: 20% hydroxypropyl-β-cyclodextran
  • Dosages: 8 mg/kg, 16 mg/kg, 32 mg/kg, and 48 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 26 mg/mL warmed (65.57 mM)
Ethanol 8 mg/mL warmed (20.17 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing. 		10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 396.49
Formula

C21H28N6O2
CAS No. 779353-01-4
Storage powder
in solvent
Synonyms PS-095760

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03484520 Recruiting Cancer - Acute Myeloid Leukemia AbbVie|Merck Sharp & Dohme Corp. July 23 2018 Phase 1
NCT03484520 Recruiting Cancer - Acute Myeloid Leukemia AbbVie|Merck Sharp & Dohme Corp. July 23 2018 Phase 1
NCT01676753 Recruiting Advanced or Metastatic Breast Cancer|Triple Negative Breast Cancer Jo Chien|Merck Sharp & Dohme Corp.|University of California San Francisco June 2016 Phase 1
NCT01676753 Recruiting Advanced or Metastatic Breast Cancer|Triple Negative Breast Cancer Jo Chien|Merck Sharp & Dohme Corp.|University of California San Francisco June 2016 Phase 1
NCT02684617 Recruiting rrCLL|rrMM|rrDLBCL Merck Sharp & Dohme Corp. March 29 2016 Phase 1
NCT02684617 Recruiting rrCLL|rrMM|rrDLBCL Merck Sharp & Dohme Corp. March 29 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to know how to reconstitute the inhibitor for in vivo studies?

  • Answer:

    S2768 (SCH727965) in 15% Captisol at 8 mg/ml is a suspension for oral administration. And it can be dissolved in 2% DMSO/30% PEG 300/ddH2O at 10 mg/ml as a clear solution for injection.

selleck catalog

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

  • Selective CDK Inhibitor

    BS-181 HCl : CDK7-selective, IC50=21 nM.

  • Selective CDK Inhibitor

    SNS-032 (BMS-387032) : CDK2-selective, IC50=48 nM.

  • Most Potent CDK Inhibitor

    LY2835219 : CDK4, IC50=2 nM; CDK6, IC50=10 nM.

  • CDK Inhibitor in Clinical Trial

    Palbociclib (PD0332991) Isethionate : Phase III for Metastatic Breast Cancer.

  • Newest CDK Inhibitor

    NU6027 : Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Related CDK Products5

  • SU9516 New

    SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.

  • Ro-3306 New

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • Purvalanol A New

    Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.

  • Palbociclib (PD-0332991) HCl

    Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

    Features:Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

  • Palbociclib (PD0332991) Isethionate

    Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

    Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.

  • Flavopiridol HCl

    Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.

  • Roscovitine (Seliciclib,CYC202)

    Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.

  • abemaciclib mesylate (LY2835219)

    abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.

  • Ribociclib (LEE011)

    Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.

  • SNS-032 (BMS-387032)

    SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1.

Tags: buy Dinaciclib (SCH727965) | Dinaciclib (SCH727965) supplier | purchase Dinaciclib (SCH727965) | Dinaciclib (SCH727965) cost | Dinaciclib (SCH727965) manufacturer | order Dinaciclib (SCH727965) | Dinaciclib (SCH727965) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID